Oncternal Therapeutics, Inc. (NASDAQ:ONCT) has a beta value of 2.07 and has seen 936,567 shares traded in the last trading session. The company, currently valued at $62.35 Million, closed the last trade at $2.79 per share which meant it lost -$0.08 on the day or -2.79% during that session. The ONCT stock price is -125.09% off its 52-week high price of $6.28 and 46.59% above the 52-week low of $1.49. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.89 Million shares traded. The 3-month trading volume is 2.43 Million shares.
The consensus among analysts is that Oncternal Therapeutics, Inc. (ONCT) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 1 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.21.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) trade information
Despite being -2.79% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Nov 16 when the ONCT stock price touched $4.88-4 or saw a rise of 42.83%. Year-to-date, Oncternal Therapeutics, Inc. shares have moved -29.37%, while the 5-day performance has seen it change -38.55%. Over the past 30 days, the shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) have changed 65.09%. Short interest in the company has seen 9.61 Million shares shorted with days to cover at 3.95.
Wall Street analysts have a consensus price target for the stock at $8, which means that the shares’ value could jump 186.74% from current levels. The projected low price target is $8 while the price target rests at a high of $8. In that case, then, we find that the current price level is +186.74% off the targeted high while a plunge would see the stock lose 186.74% from current levels.
Oncternal Therapeutics, Inc. (ONCT) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +7.2% over the past 5 years. Earnings growth for 2020 is a modest +68.6%.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT)’s Major holders
Insiders own 36.66% of the company shares, while shares held by institutions stand at 18.87% with a share float percentage of 29.8%. Investors are also buoyed by the number of investors in a company, with Oncternal Therapeutics, Inc. having a total of 31 institutions that hold shares in the company. The top two institutional holders are Armistice Capital, LLC with over 1.32 Million shares worth more than $2.24 Million. As of September 29, 2020, Armistice Capital, LLC held 5.89% of shares outstanding.
The other major institutional holder is Nantahala Capital Management, LLC, with the holding of over 1.2 Million shares as of September 29, 2020. The firm’s total holdings are worth over $2.04 Million and represent 5.37% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of June 29, 2020, the former fund manager holds about 0.96% shares in the company for having 214040 shares of worth $607.87 Thousand while later fund manager owns 64.18 Thousand shares of worth $182.26 Thousand as of June 29, 2020, which makes it owner of about 0.29% of company’s outstanding stock.